Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Different Doses of Keverprazan Dual Therapy and Keverprazan-Based Bismuth Quadruple Therapy for Eradicating Helicobacter Pylori Infection: a Multicenter, Open, Randomized Controlled Study

NCT06777732 is registered in ClinicalTrials.gov with Nanjing First Hospital, Nanjing Medical University as lead sponsor.

NCT NCT06777732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06777732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Different Doses of Keverprazan Dual Therapy and Keverprazan-Based Bismuth Quadruple Therapy for Eradicating Helicobacter Pylori Infection: a Multicenter, Open, Randomized Controlled Study
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
January 31, 2026
Enrollment
672 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection